Want to see HK:2315 full AI Analyst Report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Revenue
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Revenue
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had a revenue of 942.43M in the quarter ending Jun 30, 2026, with 24.36%. This bring the company's revenue in the last twelve months to 1.70B, Increased 23.31%. In the fiscal year ending Dec 31, 2025, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had annual revenue of 1.38B with 40.63% growth.
- Revenue (ttm)
- 1.70B
- Revenue Growth
- 48.04%
- P/S Ratio
- 12.34
- Revenue/Employee
- HKD 955,515
- Employees
- 1,443
- Market Cap
- HKD 17.02B
Revenue Chart
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38B | 398.35M | 40.63% |
| Dec 31, 2024 | 980.45M | 263.54M | 36.76% |
| Dec 31, 2023 | 716.91M | 183.03M | 34.28% |
| Dec 31, 2022 | 533.88M | 179.33M | 50.58% |
| Dec 31, 2021 | 354.56M | 101.01M | 39.84% |
| Dec 31, 2020 | 253.54M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.